Hosted on MSN2d
New CAR T-Cell Therapy Approved for LeukemiaThe FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute ...
The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...
The researchers showed that the enhanced presence of these precursor T cells did indeed bring better results in animal models ...
The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.
Vitamin D deficiency in early life may contribute to biological processes that raise the risk of autoimmune conditions, ...
FDA approves Autolus Therapeutics' Aucatzyl for adults with relapsed or refractory B-cell precursor acute lymphoblastic ...
Not only is hippocampal neurogenesis ablated, but the remaining neural precursors adopt glial fates and transplants of non-irradiated neural precursor cells fail to differentiate into neurons in ...
Aucatzyl is a CAR T-cell therapy that targets CD19 and has been designed to minimize excessive activation of the programmed T ...
The Food and Drug Administration approved obecabtagene autoleucel, or Aucatzyl from Autolus, a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or ...
A precursor of vitamin K may help slow down prostate cancer progression, a recent study conducted in mouse models of suggests ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback